Free Trial

Q2 EPS Estimate for Galectin Therapeutics Raised by Analyst

Galectin Therapeutics logo with Medical background

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - HC Wainwright boosted their Q2 2025 earnings estimates for shares of Galectin Therapeutics in a research note issued to investors on Wednesday, April 2nd. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.19) per share for the quarter, up from their prior forecast of ($0.21). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($1.06) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03).

Separately, StockNews.com cut shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, December 30th.

Read Our Latest Stock Report on Galectin Therapeutics

Galectin Therapeutics Trading Up 4.7 %

NASDAQ:GALT traded up $0.06 during midday trading on Monday, hitting $1.35. 192,253 shares of the company traded hands, compared to its average volume of 318,846. The firm has a market capitalization of $85.29 million, a P/E ratio of -1.85 and a beta of 0.79. The firm's fifty day moving average is $1.47 and its 200-day moving average is $1.87. Galectin Therapeutics has a 12-month low of $0.73 and a 12-month high of $4.27.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp lifted its stake in shares of Galectin Therapeutics by 9.3% during the 3rd quarter. State Street Corp now owns 251,014 shares of the company's stock worth $690,000 after acquiring an additional 21,399 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new stake in Galectin Therapeutics in the third quarter worth $117,000. Barclays PLC lifted its position in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company's stock worth $79,000 after purchasing an additional 21,598 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company's stock valued at $2,372,000 after purchasing an additional 20,817 shares during the period. Finally, Soltis Investment Advisors LLC bought a new position in shares of Galectin Therapeutics in the third quarter worth about $387,000. Hedge funds and other institutional investors own 11.68% of the company's stock.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

Featured Articles

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Should You Invest $1,000 in Galectin Therapeutics Right Now?

Before you consider Galectin Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.

While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy Early: 3 Tech Trends With Millionaire-Making Potential
SMCI Stumbles on Earnings: Why Some Investors Still Want In
5 Stocks to BUY NOW in May 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines